Methods and Protocols

      The Mouse Lymphoma Assay and assessment of Reduced-Risk Products

      PMI

      Published on
      May 1, 2014
      Topic
      Summary

      The Mouse Lymphoma Assay (MLA) is a widely used in vitro genotoxicity assay that can detect gene mutations induced by different types of exposures. It uses the L5178Y mouse lymphoma TK+/- cell line, detecting mutagenic events by measuring resistance to the pyridine analogue triflurothymidine (TFT).

      The MLA to assess Reduced-Risk Products

      The MLA has been shown to be effective as part of the comprehensive toxicological assessment of cigarette smoke and Reduced-Risk Product aerosols[1] and we employ the assay using a methodology underpinned by the Organisation for Economic Co-operation and Development (OECD) guidelines 476[2].

      To date we have used the MLA to test an early prototype version of our Reduced-Risk Product Platform 1 called the Electrically Heated Cigarette Smoking System Series K (EHCSS). The results are shown in the graph below where a significant reduction in mutations can be seen between EHCSS and 2R4F[3].

      Reduction in mutations between EHCSS and 2R4F. S9 fraction describes a range of metabolic enzymes derived from organ tissue. Chemical substances sometimes require metabolic activation in order to become mutagenic. Addition of a S9 tissue fraction provides the enzymes required for such activation.   Note: these data alone do not imply or represent a claim of reduced exposure or reduced risk.

       

      References:  

      [1] Schramke, H, et al. The mouse lymphoma thymidine kinase assay for the assessment and comparison of the mutagenic activity of cigarette mainstream smoke particulate phase. Toxicology, 2006. 227(3): p. 193-210. Available online at: http://www.sciencedirect.com/science/article/pii/S0300483X06004689 

      [2] OECD. OECD guideline for the testing of chemicals: in vitro mammalian cell gene mutation test. 1997. [3] Werley, MS, et al. Smoke chemistry, in vitro and in vivo toxicology evaluations of the electrically heated cigarette smoking system series K. Regul Toxicol Pharmacol, 2008. 52(2): p. 122-39. Available online at: https://www.sciencedirect.com/science/article/abs/pii/S0273230008001177

      Related Publications

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

      Pre-clinical Toxicology

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      Exposure to a Heated Tobacco Product Aerosol Is Associated with Lower Activity of Hepatic Cytochrome P450 Enzymes and Reduced Alteration in Clozapine Metabolism Than Exposure to Cigarette Smoke

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.